AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01115062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
Study NCT04107337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vocal work session with straw exercises
Description: * Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath in the straw ; (1 minute) Phonation in the straw ; (2 minutes) Make a siren in the straw ; (4 minutes) Vocalizations in the straw on the arpeggio of Rossini.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters.
Study NCT04107337 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vocal work session with open mouth exercises
Description: * Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath on a \[f\] with open mouth ; (1 minute) Phonation on the vowel \[a\] with open mouth ; (2 minutes) Make a siren on the vowel \[a\] with open mouth ; (4 minutes) Vocalizations on the vowel \[a\] on the arpeggio of Rossini with open mouth.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters.
Study NCT00774241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks
Study NCT00774241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75mg/m2 every 3 weeks for 18 weeks
Study NCT03567460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Across studies in adolescents in general population, 60 minutes of recommended daily exercise level is achieved, on average, within a total volume of 10,000-11,700 steps. The investigators will assess baseline physical activity quantitatively by using an accelerometer worn on the wrist during waking hours over a 7-day period. Each participant will be given a Garmin device to place on their wrist that will track their steps. Then patients will be asked to complete 10,000 steps daily for 6 months (acclimation over a week), which will be encouraged by daily text messages or e-mail, and weekly phone calls by the intervention team in addition to a Garmin and Facebook peer group.
Study NCT03860025 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study NCT02729207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esflurbiprofen Hydrogel Patch
Description: One patch per day for 7 days
Study NCT02729207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esflurbiprofen Hydrogel Patch
Description: One patch per day for 7 days
Study NCT03895151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk supplementation
Description: Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.
Study NCT03895151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Based Recommendation (FBR) nutrition education
Description: Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
Study NCT01058122 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of adverse drug events
Study NCT03549897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product
Study NCT03549897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90 mcg Reference Product
Description: 90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
Study NCT03549897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 180 mcg Reference Product
Description: 180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
Study NCT03549897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mcg Test Product
Description: 90 mcg Test Product - ALBUTEROL SULFATE HFA \[AMNEAL IRELAND LIMITED\]
Study NCT02658435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 150 mg
Description: Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
Study NCT02658435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo 150mg
Description: It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
Study NCT03977441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Agomelatine or PIacebo
Description: control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
Study NCT03977441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine or PIacebo
Description: control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
Study NCT01638273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
Study NCT01638273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
Study NCT04311346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MR
Description: Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
Study NCT02293616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate Rich Beetroot Juice
Description: Nitrate rich beetroot juice diet supplement will be consumed by subjects.
Study NCT02293616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02411149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
Study NCT02411149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block with Morphine
Description: Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
Study NCT02411149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local Infiltration
Description: 30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
Study NCT03161353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perjeta
Description: All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
Study NCT03161353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per the schedule specified in the respective arm.
Study NCT03330158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTS
Description: Implantation of a motorized spinal distraction rod
Study NCT00248612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
Study NCT00248612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
Study NCT01607671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol maleate
Description: Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
Study NCT04562493 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Epidural injection
Description: Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
Study NCT04562493 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transforaminal Epidural injection
Description: Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
Study NCT04562493 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transforaminal Epidural injection
Description: Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
Study NCT01012076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control vs Experimental Treatment
Description: The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
Study NCT01012076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Control vs Experimental Treatment
Description: The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
Study NCT02138435 — intervention group
Intervention type: OTHER
Intervention: MRI exercise test
Description: Measuring cardiac output with MRI during exercise on an ergometer bicycle.
Study NCT02138435 — intervention group
Intervention type: OTHER
Intervention: Gas-exchange exercise test
Description: Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
Study NCT03698331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study NCT03698331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: non-active dosage form
Study NCT03698331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: non-active dosage form
Study NCT04460456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6050
Description: Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2
Study NCT04460456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 400 mg IV
Study NCT04460456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg IV
Study NCT00678080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
Study NCT00678080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (NPH and Regular)
Description: Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
Study NCT02386306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109
Study NCT02386306 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00990938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
Study NCT00990938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subcutaneous injection once per week for four weeks
Study NCT03360747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKCEA-ANGPTL3-LRx
Description: AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.
Study NCT01690429 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Somnocheck micro
Description: Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
Study NCT02484690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered as per the regimen specified in the individual arm.
Study NCT02484690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab will be administered as per the regimen specified in the individual arm.
Study NCT02484690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab will be administered as per the regimen specified in the individual arm.
Study NCT02484690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
Study NCT02127723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection (Macrolane VRF30)
Description: Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
Study NCT03161353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
Study NCT03161353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
Study NCT03161353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
Study NCT03161353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.~Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
Study NCT02976051 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HART-CN
Description: HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
Study NCT02054754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 1
Description: Oral formulation of dexanabinol
Study NCT02054754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 2
Description: Oral formulation of dexanabinol
Study NCT02054754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 3
Description: Oral formulation of dexanabinol
Study NCT02054754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 4
Description: Oral formulation of dexanabinol
Study NCT02054754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 5
Description: Oral formulation of dexanabinol
Study NCT02054754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04807062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: tunnel bone tamps method (TBTM) was used to reduce the depressed articular fragments and then structural bicortical autologous ICBG was used to fill the valley tunnel.
Study NCT02973269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daxibotulinumtoxin type A
Description: Intramuscular injection
Study NCT02973269 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT02190318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Study NCT02190318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spirolactone
Study NCT03783091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin
Description: Single IV administration of Vitamin B12
Study NCT03783091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV administration of saline
Study NCT00248612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
Study NCT00248612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per the schedule specified in the respective arm.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm.
Study NCT02190318 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blank control
Study NCT03212820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drilling at low speed
Study NCT03212820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drilling at conventional or high speed
Study NCT00248612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progressive muscle relaxation therapy (PMR)
Description: For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.